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Autoantibodies against endothelin-1 type A receptor (ETAR) are present in systemic sclerosis complicated by lung ﬁbrosis and pulmonary
hypertension. As increased serum levels and local overproduction of endothelin-1 in the airways are reported in cystic ﬁbrosis (CF) patients, we
reasoned that anti-ETAR antibodies could be prevalent in endstage CF patients prior to lung transplantation (LTx). Also, ETAR autoantibodies are
frequently associated with autoantibodies against the angiotensin II type 1 receptor (AT1R). We analyzed the presence of anti-ETAR and anti-AT1R
autoantibodies in 43 LTx patients (chronic obstructive pulmonary disease (COPD), n = 20; CF, n = 13; interstitial lung disease (ILD), n = 1). We
observed overall higher anti-ETAR and anti-AT1R autoantibody titers in sera taken prior to LTx in the CF patient group as compared to COPD. No
difference was found in autoantibody levels between patients with CF versus ILD. In sera taken post-LTx we found the same difference in anti-
ETAR and anti-AT1R autoantibody titers between patients with CF versus COPD. No difference was found in antibody titers between sera taken
prior to or 6 months after LTx. There was no association between autoantibody levels and other relevant demographic parameters, and we found no
association between autoantibody titers and the development of the bronchiolitis obliterans syndrome. Both autoantibody titers were strongly
correlated. We hypothesize that due to prolonged exposure to bacterial infection, increased levels of AT1R and ETAR result in a deregulated
immune response causing autoantibody formation. Further research is expedient to elucidate the occurrence of autoantibodies against ETAR and
AT1R and their role in disease progression.
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Cystic fibrosis (CF) is an autosomal recessive disorder,
which mainly occurs in the Caucasian population. Patients are
often confronted with chronic infections of Gram-negative⁎ Corresponding author at: Laboratory of Translational Immunology, University
Medical Center Utrecht, F.03.821, P.O. Box 85500, 3508 GA Utrecht, The
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which results in the influx of both neutrophils and macrophages
to the site of infection [1]. In addition, CF is associated with
manifestations of autoimmunity including primary sclerosing
cholangitis, arthropathy and vasculitis. Multiple autoantibodies
are prevalent in CF, such as anti-bactericidal/permeability-
increasing protein (BPI), anti-Saccharomyces cerevisiae anti-
bodies, anti-Kα1 tubulin, anti-collagen-V, rheumatoid factors
and antinuclear antibodies [2,3], but not anti-proline–glycine–
proline or antielastin autoantibodies [4]. A delineation ofll rights reserved.
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patients at risk for developing lung damage, as has been shown
for anti-BPI which is associated with a poor prognosis of CF
disease [5].
Endothelin-1 is a protein secreted primarily by both lung
endothelial and epithelial cells and, in addition to its vasocon-
strictor activity, it has proinflammatory capacities such as priming
and stimulating neutrophils, activating mast cells, and macro-
phage stimulation that results in proinflammatory cytokine
production. Increased serum levels and local overproduction of
endothelin-1 in the airways are reported in CF patients [6]. In
addition, the overexpression of endothelin-1 is associated with
the bronchiolitis obliterans syndrome and bacterial infection in
lung transplant recipients [7,8]. Endothelin-1 acts via binding to
its type A or type B receptor and autoantibodies against
endothelin-1 type A receptor (ETAR) have already been identified
in systemic sclerosis commonly complicated by lung fibrosis and
pulmonary hypertension. ETAR autoantibodies are frequently
associated with autoantibodies against the angiotensin II type 1
receptor (AT1R) [9]. We reasoned that, beside increased levels of
endothelin-1, anti-ETAR and/or AT1R autoantibodies could be
prevalent in patients with endstage CF.
2. Patients & methods
2.1. Patients
We included 43 patients in this pilot study that underwent LTx
between January 2004 and May 2011 at our center. This study
was approved by the medical ethics committee and from all
patients informed consent was obtained. Several hours prior to
and monthly after LTx blood was obtained from each patient,
processed, and stored as serum aliquots at −80 °C until analysis.
2.2. Determination of anti-ETAR and anti-AT1R concentrations
in serum
A solid phase sandwich ELISA kit (CellTrend GmbH,
Luckenwalde, Germany) was used to measure both anti-ETAR
and anti-AT1R antibody levels in serum according to protocol
[8]. The inter- and intra-assay CVs are 8.3% and 6.3% for the
ETAR- and 11.5% and 6.9% for the AT1R-ELISA kit. The lower
limit of detection was 1 U/ml. Serum samples were thawed and
centrifuged for 10 min at 1800 rpm prior to analysis. All samples
were subjected to identical freeze–thaw cycles and analyzed in
the same experiment. The OD450 measurement was conducted
using a Multiskan EXMicroplate Photometer (ThermoScientific,
Rockford, IL). Data analysis was performed using AT1R/ETAR
analysis software provided by the manufacturer.
3. Results
3.1. Patient demographics
The analyzed patient cohort consisted of 43 LTx patients of
which 20 suffered from chronic obstructive pulmonary disease
(COPD), 13 from CF, and 10 from interstitial lung disease(ILD), including idiopathic pulmonary fibrosis (n = 3),
lymphangioleiomyomatosis (n = 2), non-specific interstitial
pneumonia (n = 1), pulmonary Langerhans cell histiocytosis
(n = 2), progressive systemic sclerosis (n = 1) and sarcoidosis
(n = 1). Nineteen of these patients developed the bronchiolitis
obliterans syndrome (BOS), among which 6 had CF as a primary
disease, during follow-up, defined according to ISHLT criteria
[10]. After transplantation immunosuppression consisted of
basiliximab, tacrolimus, mycofenolate and prednisolone. Treat-
ment with valganciclovir was initiated when a patient was
considered to be at risk for CMV. Further demographic parameters
are summarized in Table 1. Both significant differences, mean age
of inclusion and high risk for CMV reactivation, can be explained
by the younger age of CF patients at the time of transplantation.
3.2. Anti-ETAR and AT1R autoantibody titers are elevated in
CF patients
We observed overall higher anti-ETAR and anti-AT1R
autoantibody titers pre-LTx in CF patients as compared to
COPD (Fig. 1A and C). No significant difference was found in
autoantibody levels between patients with CF versus ILD. In
post-LTx sera we found the same difference in anti-ETAR and
anti-AT1R autoantibody titers between patients with CF versus
COPD (Fig. 1B and D). Unfortunately, no post-LTx serum
samples were available from three COPDs, one ILD, and on CF
patient, and could thus not be analyzed. No significant
difference was found in antibody titers between sera taken
prior to or post-LTx. There was no association between auto-
antibody levels and other relevant demographic parameters:
age, gender, type of graft, BOS incidence, ischemic time, lung
function, Pseudomonas infection, CFTR mutation, or CF
related diabetes mellitus. Anti-ETAR and anti-AT1R autoanti-
body titers were strongly correlated (p b 0.0001, r = 0.756,
data not shown).
4. Discussion
In this pilot experiment we show that autoantibodies against
both ETAR and AT1R are present in endstage lung diseases,
particularly CF. Like AT1R, ETAR is a G-protein coupled
receptor to which both an endogenous ligand, endothelin-1, and
autoantibodies may simultaneously bind resulting in a more
prolonged and detrimental biologic response.
The levels of endothelin-1 are elevated in CF patients'
sputum, compared to healthy controls and COPD patients [11],
and endothelin-1 is detectable in both the peripheral blood and
bronchoalveolar lavage (BAL) fluid of COPD patients [12]. In
our study we did not have an access to BAL fluid, since
surveillance bronchoscopy was not performed, which would
allow simultaneous analysis of endothelin-1 and autoantibody
levels, and their correlation with disease progression.
Besides being elevated in the sputum of CF patients,
endothelin-1 is also a biomarker for the detection of BOS in
serum [13]. The authors postulate that high endothelin-1 levels
arise due to an inflammatory response after lung tissue damage.
Autoantibodies against ETAR and AT1R are associated with
Table 1
Clinical and demographic profile of lung transplant patients.
Patients are divided in three diagnostic clusters, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and interstitial lung disease (ILD). Categorical
data (gender, risk for CMV/EBV, BOS) were analyzed by the Fisher's exact test, continuous variables (mean age, follow up, and the onset of BOS) by the ANOVA
test, and influence of the type of graft (bilateral or single) by the Pearson's χ2 test (SPSS version 20, IBM Corp., Armon, NY). Significant intergroup variants are
displayed in italics. Eleven out of the 13 CF patients were colonized with P. aeruginosa. One patient was colonized with S. aureus and one patient was colonized with
Stenotrophomonas maltophilia. Before transplantation infections were treated with antibiotics according to the sputum cultures. Eleven out of 13 patients were
analyzed for CFTR mutation status. Nine patients were genotyped with ΔF508, one with a homozygous 1998+5GT, and one with a G542x/R347P mutation. Two CF
patients were diagnosed by sweat test. Five patients were diagnosed with cystic fibrosis related diabetes before transplantation. Six patients were on steroids because
of a diagnosed allergic bronchopulmonary aspergillosis or to reduce inflammation. All patients were given best clinical care, had a BMI higher than 18.5, and had a
lung function b35% (range 13%–34%) prior to transplantation.
All COPD CF ILD p-Value
Total number 43 20 13 10
Gender
Male 20 6 8 6 0.129
Female 23 14 5 4
Mean age 44 (16–63) 53 (32–63) 27 (16–53) 49 (24–62) b0.0001
Mean follow up (months) 55 (5–105) 53 (5–102) 56 (5–105) 47 (9–95) 0.534
Type of graft
Bilateral 34 13 13 8 0.054
Single 9 7 0 2
Infection
EBV high risk 3 1 2 0 0.321
CMV high risk 12 2 7 3 0.023
BOS
No 24 10 7 7 0.574
Yes 19 10 6 3
Onset of BOS (months) 27 (5–81) 30 (6–82) 30 (5–49) 12 (10–18) 0.339
Ischemic time (minutes)
Bilateral 305 (120–1460) 245 (124–405) 282 (145–433) 438 (120–1460) 0.069
Single 238 (161–337) 226 (187–265) 249 (161–337) 0.833
COPD
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Fig. 1. ETAR and AT1R autoantibody titers pre-and post-lung transplantation. Pre- (A and C) and post-transplantation (B and D) antibody levels against ETAR (A and
B) and AT1R (C and D) are displayed in U/ml. Cut-off levels to define positivity were set according to previously described healthy control values (see Patients and
methods). Each dot represents the result from 1 serum sample. No significant differences between CF and ILD were found between pre- and post-LTx anti-ETAR,
p = 0.31 and p = 0.38, and pre- and post-LTx anti-AT1R autoantibodies, p = 0.28 and p = 0.58 respectively. A Mann–Whitney rank-sum test was used for statistical
analysis (GraphPad Prism version 5.03, GraphPad Software Inc., San Diego, CA).
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we could not find a correlation between autoantibody titers and
development of BOS, which is hallmarked by fibrotic
development in the lungs [10]. Also, both anti-ETAR and
anti-AT1R autoantibodies have been identified in episodes of
cellular and antibody-mediated rejection after heart transplan-
tation, and anti-AT1R autoantibodies are associated with
antibody mediated rejection after kidney transplantation [14].
However in our study we were unable to distinguish cellular
and antibody mediated rejection due to the absence of lung
biopsy material.
We show for the first time that autoantibodies against both
ETAR and AT1R are elevated in endstage CF patients. Although
both receptors are involved in a common vasocontrictive
pathway, their natural ligands differ in functional capacities.
AT1R autoantibodies are agonistic [15], but we can only
speculate on the role of both ETAR and AT1R autoantibodies
and their part in CF pathology. We hypothesize that due to
prolonged exposure to bacterial infection, increased levels of
AT1R and ETAR result in a deregulated immune response
causing autoantibody formation. The development of these auto-
antibodies would then be a consequence of disease progression.
Anti-ETAR and anti-AT1R autoantibodies could thus have an
additive value in disease prognosis for young CF patients,
which is desired, since besides genetic background, more
factors can contribute to their respective clinical outcome [5].
However, we only analyzed endstage lung disease patients,
indicating that further research is expedient in a follow-up
cohort of different lung diseases, to elucidate the occurrence of
autoantibodies against ETAR and AT1R and their role in
disease progression.
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